BioCentury
ARTICLE | Company News

Duke spinout Grid gets IP for CFH antibodies

August 22, 2017 9:31 PM UTC

Duke University granted Grid Therapeutics LLC (Durham, N.C.), formerly Cue Biologics LLC, exclusive rights to IP covering antibodies that target complement factor H (factor H; CFH) to treat cancer, and CFH-related diagnostics. Duke received a stake in Grid as part of the deal.

In early 2019, Grid plans to start Phase I testing of lead candidate GT103, a recombinant IgG3 mAb targeting CFH, to treat advanced solid tumors...